HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Humacyte, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.40−0.03 (-6.50%)
Close on Oct 19, 2026
- Market cap
- $93.93M
- P/E (TTM)
- –
- Dividend yield
- –
Humacyte, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $2.04M | $1.74M | $1.39M | $950.00K | $247.00K | $147.00K | $0 | 96.2% | +726.3% |
| Contract Revenue [Member] | $80.00K | $281.00K | $649.00K | $621.00K | $571.00K | $370.00K | $0 | 3.8% | -86.0% |
By region
From the segment and revenue-disaggregation notes of Humacyte's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.